4d Molecular Therapeutics, INC 8-K filings

4D Molecular Therapeutics announced positive 2-year data from its Phase 2b PRISM trial for 4D-150, showing consistent visual acuity, disease control, and significant treatment burden reduction in wet AMD patients.

4D Molecular Therapeutics has entered into a significant loan and security agreement with Hercules Capital, Inc., potentially providing up to $200 million in term loans to fund its operations and development.

4D Molecular Therapeutics appointed CFO Kristian Humer as Principal Accounting Officer, succeeding Ashoo Gupta, effective March 25, 2026.

4D Molecular Therapeutics announced full year 2025 financial results, highlighted by rapid Phase 3 trial enrollment for 4D-150 and a strengthened financial position.

4D Molecular Therapeutics exchanged common stock for pre-funded warrants with key institutional investors, adjusting its capital structure.

4D Molecular Therapeutics announced a leadership transition, a new board appointment, and an estimated $514 million in cash, cash equivalents, and marketable securities.

4D Molecular Therapeutics announced protocol amendments to increase patient enrollment in its 4D-150 wet AMD Phase 3 trials to support global regulatory submissions.

4D Molecular Therapeutics, Inc. announced the appointment of Kristian Humer, a seasoned biotechnology and investment banking executive, as its new Chief Financial Officer.

4D Molecular Therapeutics reports Q3 2025 financial results, a strategic partnership, and positive clinical data, extending its cash runway into H2 2028.

4D Molecular Therapeutics successfully closed an equity offering, raising approximately $93.3 million through the sale of common stock and pre-funded warrants.

4D Molecular Therapeutics announced positive interim 1.5to 3.5-year data from its Phase 1/2 PRISM clinical trial for 4D-150 in wet age-related macular degeneration, alongside a preliminary cash estimate of $372.2 million.

4D Molecular Therapeutics partners with Otsuka Pharmaceutical for exclusive development and commercialization of 4D-150 in Asia-Pacific markets, securing an $85 million upfront payment and significant potential milestones.

4D Molecular Therapeutics, Inc. announced the appointment of Ashoo Gupta as Principal Financial Officer and Principal Accounting Officer and updated its bylaws to revise advance notice procedures for stockholder proposals and director nominations.

4D Molecular Therapeutics reported Q2 2025 financial results, accelerated its lead wet AMD program, and streamlined operations, extending its cash runway into 2028.

4D Molecular Therapeutics announced accelerated timelines for its lead wet AMD clinical trial, a 25% workforce reduction to extend cash runway, and the resignation of its Chief Financial and Business Officer.

4D Molecular Therapeutics, Inc. announced the successful outcomes of its 2025 Annual Meeting of Stockholders, with all four proposals, including director elections and auditor ratification, receiving majority approval.

4D Molecular Therapeutics announces Q1 2025 financial results, highlighting the initiation of Phase 3 clinical trials for 4D-150 in wet AMD and progress in other key programs.

4D Molecular Therapeutics announces full year 2024 financial results, operational highlights, and upcoming milestones, highlighting progress in wet AMD, DME, and cystic fibrosis programs.

4D Molecular Therapeutics reports positive 52-week interim data from its Phase 2b PRISM clinical trial for 4D-150 in wet AMD, showing significant reduction in supplemental injections and improved visual acuity.

4D Molecular Therapeutics has strategically focused its pipeline, leading to an extended cash runway into 2028 and positive interim data from a key clinical trial.

4D Molecular Therapeutics exchanged 535,000 common shares for a pre-funded warrant with RA Capital, exercisable at a nominal price.

4D Molecular Therapeutics announced positive interim data for its wet AMD treatment, 4D-150, and provided updates on its clinical programs and financial position.

4D Molecular Therapeutics reported positive interim results from its Phase 1/2 PRISM trial for 4D-150 in wet AMD, showing significant reductions in treatment burden, and announced the design for its Phase 3 4FRONT trial.

4D Molecular Therapeutics reported positive interim results for its wet AMD treatment, 4D-150, and strengthened its leadership team, while also providing a financial update for the second quarter of 2024.

4D Molecular Therapeutics will present interim data from its Phase 1/2 PRISM clinical trial of 4D-150 for wet age-related macular degeneration at a medical conference in September 2024.

4D Molecular Therapeutics reported positive interim 24-week data from its Phase 2 PRISM trial for wet AMD treatment 4D-150, showing significant reductions in injection rates and improvements in visual acuity.

4D Molecular Therapeutics has established an at-the-market sales agreement with Leerink Partners to potentially sell up to $250 million of its common stock.

4D Molecular Therapeutics held its 2024 Annual Meeting, electing David Kirn, M.D. as a Class I director and ratifying PricewaterhouseCoopers LLP as its independent auditor for the fiscal year ending December 31, 2024.

4D Molecular Therapeutics reported positive interim clinical data across multiple programs and a strong cash position following a successful public offering in the first quarter of 2024.

4D Molecular Therapeutics announced positive clinical data across multiple programs and a successful $300 million follow-on offering, extending their operational runway into the first half of 2027.